MedTrace Logo

Effects of Temporary Abstinence and Expressive Writing on Gaming

NCT07068035 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 321

Last updated 2025-07-16

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate if an intervention combining temporary abstinence and expressive writing can mitigate gaming problems in young adult regular gamers. The main questions it aims to answer are:

\- Does intervention combining temporary abstinence and expressive writing reduces problematic gaming and gaming time?

Researchers will compare the treatment group to a control group (gaming as per usual and control writing) to examine if the intervention works to mitigate gaming problems.

Participants will:

* Temporarily abstain from video games for a period of 7 days and engage in 4 expressive writing exercises during this intervention period
* Answer three surveys: a baseline survey before the start of the intervention, a post survey after the 7-day intervention, and a follow-up survey 1 month after the post survey.

Conditions

  • Problematic Video Gaming

Interventions

BEHAVIORAL

Temporary abstinence and expressive writing

This brief, self-administered intervention combined both temporary gaming abstinence and gaming-focused expressive writing to mitigate gaming problems

BEHAVIORAL

Gaming as per usual and control writing

Participants continued with their usual gaming routine and engaged in control writing exercises for 15 minutes every other day for a total of 4 sessions

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-02
Primary Completion
2024-11-11
Completion
2024-11-11

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07068035 on ClinicalTrials.gov